{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:47:17Z","timestamp":1777592837387,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clinthera.2020.06.021","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T21:38:59Z","timestamp":1597441139000},"page":"1715-1727.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association Between the Overall Risk of Prostate Cancer and Use of Calcium Channel Blockers: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"42","author":[{"given":"Hui","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1797-2215","authenticated-orcid":false,"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.06.021_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/iju.13593","article-title":"Epidemiology of prostate cancer in Asian countries","volume":"25","author":"Kimura","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib2","first-page":"267","article-title":"T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells","volume":"41","author":"Ohkubo","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/s19010139","article-title":"Extracellular electrophysiology in the prostate cancer cell model PC-3","volume":"19","author":"Cabello","year":"2019","journal-title":"Sensors (Basel, Switzerland)"},{"key":"10.1016\/j.clinthera.2020.06.021_bib4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1476-5381.2012.01908.x","article-title":"Functional role of T-type calcium channels in tumour growth and progression: prospective in cancer therapy","volume":"166","author":"Santoni","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(96)04277-8","article-title":"Calcium-channel blockade and incidence of cancer in aged populations","volume":"348","author":"Pahor","year":"1996","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2020.06.021_bib6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(97)80084-0","article-title":"Calcium-channel blockers and risk of cancer","volume":"349","author":"Jick","year":"1997","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clinthera.2020.06.021_bib7","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","article-title":"Cancer risk in users of calcium channel blockers","volume":"29","author":"Olsen","year":"1997","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"10.1016\/j.clinthera.2020.06.021_bib8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","article-title":"Calcium channel blockers and the risk of cancer","volume":"279","author":"Rosenberg","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2020.06.021_bib9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0895-7061(98)00176-9","article-title":"Calcium channel blocker use and the risk of prostate cancer","volume":"11","author":"Vezina","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.clinthera.2020.06.021_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165::AID-CNCR21>3.0.CO;2-G","article-title":"Cancer risk and mortality in users of calcium channel blockers. A cohort study","volume":"89","author":"Sorensen","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2020.06.021_bib11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S1047-2797(01)00246-0","article-title":"Hypertension, heart rate, use of antihypertensives, and incident prostate cancer","volume":"11","author":"Fitzpatrick","year":"2001","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/1055-9965.EPI-03-0093","article-title":"Inverse association between prostate cancer and the use of calcium channel blockers","volume":"13","author":"Debes","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clinthera.2020.06.021_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","article-title":"Antihypertensive drug use and the risk of prostate cancer (Canada)","volume":"15","author":"Perron","year":"2004","journal-title":"Cancer Causes & Control"},{"key":"10.1016\/j.clinthera.2020.06.021_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10294","article-title":"Association between captopril, other antihypertensive drugs and risk of prostate cancer","volume":"58","author":"Ronquist","year":"2004","journal-title":"The Prostate"},{"key":"10.1016\/j.clinthera.2020.06.021_bib15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/pds.1656","article-title":"Long-term use of antihypertensive drugs and risk of cancer","volume":"17","author":"Assimes","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2020.06.021_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10552-008-9280-0","article-title":"Use of blood-pressure-lowering medication and risk of prostate cancer in the cancer prevention study II nutrition cohort","volume":"20","author":"Rodriguez","year":"2009","journal-title":"Cancer Causes & Control"},{"key":"10.1016\/j.clinthera.2020.06.021_bib17","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s10552-011-9819-3","article-title":"The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study","volume":"22","author":"Kemppainen","year":"2011","journal-title":"Cancer Causes & Control"},{"key":"10.1016\/j.clinthera.2020.06.021_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050893","article-title":"Long-term use of angiotensin receptor blockers and the risk of cancer","volume":"7","author":"Azoulay","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.06.021_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study","volume":"37","author":"Holmes","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/pros.22632","article-title":"The association between calcium channel blocker use and prostate cancer outcome","volume":"73","author":"Poch","year":"2013","journal-title":"The Prostate"},{"issue":"1","key":"10.1016\/j.clinthera.2020.06.021_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009147","article-title":"Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD)","volume":"6","author":"Grimaldi-Bensouda","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2020.06.021_bib22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/pros.23267","article-title":"Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status","volume":"77","author":"Geybels","year":"2017","journal-title":"The Prostate"},{"key":"10.1016\/j.clinthera.2020.06.021_bib23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/aja.aja_26_17","article-title":"Antiarrhythmic drug usage and prostate cancer: a population-based cohort study","volume":"20","author":"Kao","year":"2018","journal-title":"Asian J Androl"},{"key":"10.1016\/j.clinthera.2020.06.021_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/21681805.2018.1559882","article-title":"Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort","volume":"52","author":"Siltari","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib25","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/phar.2266","article-title":"Calcium channel blocker use and the risk for prostate cancer: a population-based nested case-control study","volume":"39","author":"Rotshild","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2020.06.021_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ijc.31802","article-title":"Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland\u2014a nationwide cohort study","volume":"144","author":"Santala","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinthera.2020.06.021_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12894-018-0318-7","article-title":"Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies","volume":"18","author":"Cao","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/jcpt.12673","article-title":"Calcium channel blockers and the incidence of breast and prostate cancer: a meta-analysis","volume":"43","author":"Thakur","year":"2018","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2020.06.021_bib29","first-page":"e94","article-title":"Calcium channel blocker modulates androgen receptor-mediated gene expression and induces cytotoxicity in prostate cancer cells","volume":"1","author":"Graham","year":"2012","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00441-014-1936-3","article-title":"The role of L-type voltage-gated calcium channels Cav1.2 and Cav1.3 in normal and pathological brain function","volume":"357","author":"Berger","year":"2014","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.clinthera.2020.06.021_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.urolonc.2013.05.011","article-title":"Cav1.3 channel alpha1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers","volume":"32","author":"Chen","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clinthera.2020.06.021_bib32","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1002\/cncr.27677","article-title":"Prospective study on metabolic factors and risk of prostate cancer","volume":"118","author":"Haggstrom","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2020.06.021_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1464-410X.2010.09703.x","article-title":"The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study","volume":"107","author":"Wallner","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clinthera.2020.06.021_bib34","doi-asserted-by":"crossref","first-page":"31358","DOI":"10.1038\/srep31358","article-title":"Hypertension and risk of prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Liang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2020.06.021_bib35","first-page":"113","article-title":"The association between hypertension and prostate cancer","volume":"19","author":"Navin","year":"2017","journal-title":"Rev Urol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:49Z","timestamp":1758963169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820303313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0149291820303313"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.06.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between the Overall Risk of Prostate Cancer and Use of Calcium Channel Blockers: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}